Literature DB >> 20880925

Insiders criticise FDA's decision not to withdraw rosiglitazone.

Deborah Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20880925     DOI： 10.1136/bmj.c5333

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Authors:  Stacie B Dusetzina; G Caleb Alexander
Journal:  J Gen Intern Med       Date:  2011-06       Impact factor: 5.128

2.  How Did Multiple FDA Actions Affect the Utilization and Reimbursed Costs of Thiazolidinediones in US Medicaid?

Authors:  Jason C Hsu; Dennis Ross-Degnan; Anita K Wagner; Fang Zhang; Christine Y Lu
Journal:  Clin Ther       Date:  2015-05-11       Impact factor: 3.393

3.  Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases.

Authors:  Ajit A Kulkarni; Collynn F Woeller; Thomas H Thatcher; Sesquile Ramon; Richard P Phipps; Patricia J Sime
Journal:  PPAR Res       Date:  2012-06-18       Impact factor: 4.964

Review 4.  Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Authors:  Yoon Kong Loke; Chun Shing Kwok; Sonal Singh
Journal:  BMJ       Date:  2011-03-17

5.  Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2016-07-12

6.  Role of Peroxisome Proliferator-Activated Receptor-γ in Vascular Inflammation.

Authors:  Kousei Ohshima; Masaki Mogi; Masatsugu Horiuchi
Journal:  Int J Vasc Med       Date:  2012-07-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.